Safety of Phosphodiesterase-5 Inhibitors in Valvular Heart Disease.
J Cardiovasc Pharmacol
; 78(3): 372-376, 2021 09 01.
Article
en En
| MEDLINE
| ID: mdl-34074904
ABSTRACT
ABSTRACT Erectile dysfunction is a common entity in clinical practice. Primary erectile dysfunction, not related to vasculopathy or psychiatric disorder, can be readily treated with phosphodiesterase inhibitors. These drugs have many physiologic effects that can alter a patient's hemodynamic profile considerably, especially in the presence of concomitant structural heart disease, specifically valvular heart disease. Although some contraindications to the use of PDE5 inhibitors in patients with cardiovascular disease are defined, the effect of these drugs in the presence of valvular heart disease is not well documented. The purpose of this review is to analyze the data regarding the safety of PDE5 inhibitors in patients with valvular heart disease.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Erección Peniana
/
Fosfodiesterasas de Nucleótidos Cíclicos Tipo 5
/
Inhibidores de Fosfodiesterasa 5
/
Enfermedades de las Válvulas Cardíacas
/
Hemodinámica
/
Disfunción Eréctil
Tipo de estudio:
Etiology_studies
/
Risk_factors_studies
Límite:
Animals
/
Humans
/
Male
Idioma:
En
Revista:
J Cardiovasc Pharmacol
Año:
2021
Tipo del documento:
Article